Arca
Skip to content
Tools
Tools

CD19: B-lymphocyte antigen CD19

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Functions as a coreceptor for the B-cell antigen receptor complex (BCR) on B-lymphocytes.

  • Drugs that act on it: 17
  • Approved: 8
  • In phases 1 to 3: 8
  • Sponsors: 11

Who Is On It, and How Far Along

Every drug ChEMBL records acting on CD19, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody
  • Antibody-drug conjugate
  • Other

Approved8

  • Blinatumomab
  • Tafasitamab
  • Axicabtagene ciloleucel
  • Loncastuximab tesirine
  • Inebilizumab
  • Tisagenlecleucel
  • Brexucabtagene autoleucel
  • Obecabtagene autoleucel

Phase 32

  • Lisocabtagene maraleucel
  • Obexelimab

Phase 24

  • Coltuximab ravtansine
  • Denintuzumab mafodotin
  • Oncolysin b
  • Taplitumomab paptox

Phase 12

  • AMG-729
  • MDX-1342

Preclinical or unknown1

  • Denintuzumab

Sponsors

Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

  • Autolus Limited16%
  • Kite, A Gilead Company16%
  • Shenzhen Fosun Kairos Biotechnology Co., Ltd.16%

Modalities

Drugs on this target by ChEMBL molecule type.

  • Antibody529%
  • Antibody-drug conjugate424%
  • Other847%

The Landscape

Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 15 of 17 act as: B-lymphocyte antigen CD19 binding agent; the rest name their own mechanism.
BlinatumomabApprovedAmgenAntibodyCross-linking agentB-lymphocyte antigen CD19 cross-linking agent119Boxed warning
TafasitamabApprovedMorphoSys USAntibodyBinding agent—43—
Axicabtagene ciloleucelApprovedShenzhen Fosun Kairos Biotechnology Co., Ltd.GeneBinding agent—34Boxed warning
Loncastuximab tesirineApprovedADC TherapeuticsAntibody-drug conjugateBinding agent—21—
InebilizumabApprovedAmgenAntibodyBinding agent—18—
TisagenlecleucelApprovedNovartis PharmaceuticalsCellBinding agent—15Boxed warning
Brexucabtagene autoleucelApprovedKite, A Gilead CompanyGeneBinding agent—13Boxed warning
Obecabtagene autoleucelApprovedAutolus LimitedGeneBinding agent—7Boxed warning
Lisocabtagene maraleucelPhase 3Bristol-Myers SquibbGeneBinding agent—19—
ObexelimabPhase 3Zenas BioPharma (USA), LLCAntibodyInhibitorB-lymphocyte antigen CD19 inhibitor4—
Coltuximab ravtansinePhase 2SanofiAntibody-drug conjugateBinding agent—0—
Denintuzumab mafodotinPhase 2PfizerAntibody-drug conjugateBinding agent—0—
Oncolysin bPhase 2—OtherBinding agent—0—
Taplitumomab paptoxPhase 2—Antibody-drug conjugateBinding agent—0—
AMG-729Phase 1—OtherBinding agent—0—
MDX-1342Phase 1Bristol-Myers SquibbOtherBinding agent—0—
DenintuzumabPreclinical or unknown—AntibodyBinding agent—0—

Open Trials

The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 72 in all, from ClinicalTrials.gov.
Tafasitamab, Lenalidomide, Rituximab, and Orelabrutinib for Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaTafasitamabPhase 2Not yet recruitingSun Yat-sen University2026-11-16
Disulfiram for Preventing Treatment Complications in Patients Undergoing CAR T-cell Therapy for Relapsed or Refractory Diffuse Large B-cell LymphomaAxicabtagene ciloleucelPhase 1 / Phase 2Not yet recruitingUniversity of Michigan Rogel Cancer Center2026-11-12
Venetoclax Plus Inotuzumab Reduced-Intensity Induction Sequentially Followed by Blinatumomab in B-ALLBlinatumomabNot applicableNot yet recruitingInstitute of Hematology & Blood Diseases Hospital, China2026-11-06
A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010)TafasitamabPhase 2 / Phase 3Not yet recruitingMerck Sharp & Dohme LLC2026-11-05
Asciminib-Based Induction Therapy for the Treatment of Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaBlinatumomabPhase 1Not yet recruitingCity of Hope Medical Center2026-11-03
Study to Evaluate the Feasibility and Safety of Autologous Cytokine-Induced Killer Cells (CIK_D332) in Combination With Tafasitamab and Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaTafasitamabPhase 1Not yet recruitingIstituto Oncologico Veneto IRCCS2026-10-30
Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell TherapyAxicabtagene ciloleucel, Brexucabtagene autoleucelPhase 2RecruitingUniversity of Michigan Rogel Cancer Center2026-10-23
BLinatumomab and iNKT in Relapsed B-Cell ALLBlinatumomabPhase 1Not yet recruitingUNC Lineberger Comprehensive Cancer Center2026-10-09
Inebilizumab for the Treatment of Patients With Type 1 Autoimmune PancreatitisInebilizumabPhase 4RecruitingRuijin Hospital2026-10-07
Exploratory Study on the Efficacy and Safety of Low-Dose Blinatumomab in the Treatment of Moderate to Severe Primary Sjögren's SyndromeBlinatumomabPhase 2Not yet recruitingBeijing Tongren Hospital2026-10-01
A Phase 3 Study of Inebilizumab in Participants With Primary Membranous NephropathyInebilizumabPhase 3RecruitingAmgen2026-10-01
Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALLBlinatumomabPhase 2Not yet recruitingInstitute of Hematology & Blood Diseases Hospital, China2026-09-25
Liso-Cel in Relapsed/Refractory Marginal Zone LymphomaLisocabtagene maraleucel—Active, not recruitingBristol-Myers Squibb2026-08-20
Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin LymphomaAxicabtagene ciloleucel, Brexucabtagene autoleucelPhase 2RecruitingVanderbilt-Ingram Cancer Center2026-08-13
Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular LymphomaTafasitamabPhase 2RecruitingUniversity of Washington2026-07-28
CD19-B Cell Depletion in PAIS-ME/CFS PatientsInebilizumabPhase 2Not yet recruitingCharite University, Berlin, Germany2026-07-24
Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple MyelomaAxicabtagene ciloleucel, Lisocabtagene maraleucelPhase 1RecruitingWeill Medical College of Cornell University2026-07-24
A Study of Injectable BLB101 and Blincyto® in Adult Participants With R/R CD19+ B-ALLBlinatumomabPhase 3Not yet recruitingInstitute of Hematology & Blood Diseases Hospital, China2026-07-23
GLORY: Glofit-GemOx With Liso-Cel For LymphomaLisocabtagene maraleucelPhase 2RecruitingMassachusetts General Hospital2026-07-17
Evaluating the Treatment Outcomes of Tafasitamab in Patients With Relapsed/ Refractory Diffuse Large B-cell Lymphoma: a Real-world Evidence StudyTafasitamab—Active, not recruitingTTY Biopharm2026-07-16
Safety and Efficacy of the Bispecific T-Cell Engager (BiTE) as Conditioning Regimen for ABO-incompatible Living Donor Kidney TransplantationBlinatumomabEarly phase 1Not yet recruitingWest China Hospital2026-07-15
Safety and Efficacy of BiTE in Desensitization Therapy for Highly Sensitized Kidney Transplant Candidates With cPRA ≥ 90%BlinatumomabPhase 4Not yet recruitingWest China Hospital2026-07-08
Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell LymphomaTisagenlecleucelPhase 1RecruitingNathan Denlinger2026-06-30
Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell LymphomaBrexucabtagene autoleucelPhase 2RecruitingVanderbilt-Ingram Cancer Center2026-06-29
Efficacy and Safety of Sequential Autologous Hematopoietic Stem Cell Transplantation Combined With Tafasitamab, Lenalidomide, and Standard Immunochemotherapy for Relapsed/Refractory Diffuse Large B-cell LymphomaTafasitamabPhase 2Active, not recruitingThe First Affiliated Hospital of Soochow University2026-06-02
A Study of Automated Axicabtagene Ciloleucel for R/R Large B-cell Lymphoma.Axicabtagene ciloleucelEarly phase 1RecruitingShenzhen Fosun Kairos Biotechnology Co., Ltd.2026-05-26
A Trial of Inebilizumab in Participants With Autoimmune HepatitisInebilizumabPhase 3RecruitingAmgen2026-05-20
A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and LenalidomideTafasitamabPhase 2Not yet recruitingInstitute of Hematology & Blood Diseases Hospital, China2026-05-14
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaTafasitamabPhase 2RecruitingCity of Hope Medical Center2026-05-12
Loncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO)Loncastuximab tesirinePhase 1 / Phase 2RecruitingUniversity of Utah2026-05-07
CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors.Axicabtagene ciloleucelPhase 2RecruitingZhejiang Cancer Hospital2026-04-20
Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line TherapyAxicabtagene ciloleucelPhase 3Active, not recruitingKite, A Gilead Company2026-03-18
A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic LeukemiaObecabtagene autoleucelPhase 2RecruitingMemorial Sloan Kettering Cancer Center2026-02-10
A Non-Interventional Study PASS to Characterize Secondary Malignancies of Tcell Origin Following Tisagenlecleucel TherapyTisagenlecleucel—RecruitingNovartis Pharmaceuticals2026-01-30
Glofitamab Combined With CAR-T Therapy in R/R DLBCLAxicabtagene ciloleucelPhase 2Not yet recruitingRuijin Hospital2026-01-08
Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell LymphomaLisocabtagene maraleucelPhase 2RecruitingM.D. Anderson Cancer Center2026-01-05
A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid MalignanciesLoncastuximab tesirinePhase 1RecruitingJanssen Research & Development, LLC2025-12-29
Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RDInebilizumabPhase 2RecruitingAmgen2025-10-30
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)Loncastuximab tesirinePhase 2RecruitingUniversität Münster2025-09-29
Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaLisocabtagene maraleucelPhase 2RecruitingFred Hutchinson Cancer Center2025-09-26
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell TherapyLisocabtagene maraleucelPhase 3RecruitingLyell Immunopharma, Inc.2025-09-23
Inectolizumab With Steroid Optimization in Newly Treated NMOSDInebilizumabNot applicableNot yet recruitingFirst Affiliated Hospital of Wenzhou Medical University2025-09-08
Obe-cel in Refractory Progressive Forms of Multiple SclerosisObecabtagene autoleucelPhase 1RecruitingAutolus Limited2025-08-24
Slow vs. Rapid Glucocorticoids Tapering With Inebilizumab in NMOSDInebilizumabPhase 3Not yet recruitingTianjin Medical University General Hospital2025-08-20
Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)Obecabtagene autoleucelPhase 2RecruitingAutolus Limited2025-07-08
Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL)Obecabtagene autoleucelPhase 2RecruitingM.D. Anderson Cancer Center2025-07-08
NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell LymphomaLisocabtagene maraleucelPhase 1RecruitingWashington University School of Medicine2025-07-04
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System LymphomaLisocabtagene maraleucelPhase 2RecruitingJuno Therapeutics, Inc., a Bristol-Myers Squibb Company2025-06-11
Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSDInebilizumabPhase 4RecruitingMassachusetts General Hospital2025-06-08
Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)Loncastuximab tesirinePhase 1RecruitingThe University of Texas Health Science Center at San Antonio2025-05-18
Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy FailureLoncastuximab tesirinePhase 2RecruitingIstituto Clinico Humanitas2025-04-09
Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell LymphomaLoncastuximab tesirinePhase 2RecruitingUniversity of Miami2025-04-09
Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)Loncastuximab tesirinePhase 2RecruitingUniversity of Utah2025-01-23
Long-term Follow up Local Registry Study of Kymriah in South KoreaTisagenlecleucel—RecruitingNovartis Pharmaceuticals2025-01-21
Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)Loncastuximab tesirinePhase 1RecruitingUniversity of Utah2024-09-23
A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)ObexelimabPhase 2Active, not recruitingZenas BioPharma (USA), LLC2024-08-21
A Study of Obexelimab in Patients With Systemic Lupus ErythematosusObexelimabPhase 2Active, not recruitingZenas BioPharma (USA), LLC2024-08-19
Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCLBrexucabtagene autoleucelPhase 2RecruitingH. Lee Moffitt Cancer Center and Research Institute2024-08-14
CAR-T-cell Treatment for Untreated High Risk MANtle Cell LymphomaBrexucabtagene autoleucelPhase 2RecruitingChristian Schmidt, MD2024-07-01
Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell MalignanciesTisagenlecleucelPhase 1RecruitingStanford University2024-05-10
Obe-cel in Adolescent [Applicable in UK Only] and Adult Severe, Refractory Systemic Lupus ErythematosusObecabtagene autoleucelPhase 1Active, not recruitingAutolus Limited2024-03-27
Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomabBrexucabtagene autoleucelPhase 1 / Phase 2RecruitingM.D. Anderson Cancer Center2024-03-01
Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic LeukemiaBrexucabtagene autoleucelPhase 2Active, not recruitingKite, A Gilead Company2024-02-12
A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell LymphomaBrexucabtagene autoleucelPhase 2RecruitingM.D. Anderson Cancer Center2024-01-19
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)Obecabtagene autoleucelPhase 1RecruitingAutolus Limited2023-12-15
A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular LymphomaTisagenlecleucelPhase 3Active, not recruitingNovartis Pharmaceuticals2023-06-05
Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available ImmunotherapyTisagenlecleucel—RecruitingStanford University2023-05-18
A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)ObexelimabPhase 3Active, not recruitingZenas BioPharma (USA), LLC2023-03-27
A Phase 3 Study of Obexelimab in Patients With IgG4-Related DiseaseObexelimabPhase 3Active, not recruitingZenas BioPharma (USA), LLC2022-12-22
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaTisagenlecleucelPhase 2RecruitingSWOG Cancer Research Network2022-12-01
Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte MalignanciesTisagenlecleucel—RecruitingNovartis Pharmaceuticals2022-09-15
A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)Obecabtagene autoleucelPhase 1 / Phase 2Active, not recruitingAutolus Limited2020-05-27

Diseases Most Associated With It

Open Targets association score, 0 to 1; all associations
Immunodeficiency, common variable, 3
0.67
Common variable immunodeficiency
0.60
Neoplasm
0.53
B-cell non-Hodgkin lymphoma
0.51
Decreased circulating immunoglobulin concentration
0.47
Recurrent infections associated with rare immunoglobulin isotypes deficiency
0.46

Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3390821, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P15391, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.